Cargando…

Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients

OBJECTIVES: We aimed to assess the effectiveness and nephrotoxicity of polymyxin B in critically ill patients with nosocomial pneumonia and to evaluate the utility of its therapeutic drug monitoring (TDM). METHODS: We retrospectively analyzed patients who received polymyxin B treatment for ≥48 h sin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Qinghua, Wang, Qianlin, Chen, Ziying, Chen, Wenqian, Zhan, Qingyuan, Wang, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366561/ https://www.ncbi.nlm.nih.gov/pubmed/35586931 http://dx.doi.org/10.1111/crj.13493

Ejemplares similares

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia
por: Zeng, Huihui, et al.
Publicado: (2021)

Coinfection and superinfection in ICU critically ill patients with severe COVID-19 pneumonia and influenza pneumonia: are the pictures different?
por: Chen, Ziying, et al.
Publicado: (2023)

Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients
por: Deng, Yang, et al.
Publicado: (2022)

Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis
por: Wang, Jiang-Lin, et al.
Publicado: (2022)

Nosocomial pneumonia in critically ill patients
por: Dandagi, Girish L.
Publicado: (2010)

2542. Attenuation of Polymyxin and Aminoglycoside-Associated Nephrotoxicity
por: Hudson, Cole, et al.
Publicado: (2023)

Effect of Different Dosage Frequency of Polymyxin B on Rat Nephrotoxicity
por: Sun, Wenrui, et al.
Publicado: (2021)

Polymyxin B Nephrotoxicity: From Organ to Cell Damage
por: Vattimo, Maria de Fátima Fernandes, et al.
Publicado: (2016)

Curcumin Supplementation Alleviates Polymyxin E-Induced Nephrotoxicity
por: Vazin, Afsaneh, et al.
Publicado: (2020)

The Determination of Polymyxin B in Critically Ill Patients by the HPLC-MS/MS Method
por: Wang, Yirong, et al.
Publicado: (2023)

Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity
por: Lu, Jing, et al.
Publicado: (2022)

Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B
por: Gallardo-Godoy, Alejandra, et al.
Publicado: (2016)

The Susceptibility of MDR-K. Pneumoniae To Polymyxin B Plus Its Nebulised Form Versus Polymyxin B Alone in Critically Ill South Asian Patients
por: Hasan, Md. Jahidul, et al.
Publicado: (2021)

Efficacy and nephrotoxicity of polymyxin B in elderly patients with carbapenem resistant bacterial infection
por: Xia, G. L., et al.
Publicado: (2023)

Nephrotoxicity and Efficacy Assessment of Polymyxin B Use in Renal Transplant Patients
por: Wen, Yu-Xin, et al.
Publicado: (2022)

Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients
por: Liang, Danhong, et al.
Publicado: (2023)

Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study
por: Zheng, Guanhao, et al.
Publicado: (2022)

Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study
por: Tang, Tiantian, et al.
Publicado: (2023)

98. Clinical and Pharmacoeconomic Impact of Rapid Diagnostic Pneumonia Panel in Critically Ill Patients Admitted with Nosocomial Pneumonia
por: Kerr, Kathryn H, et al.
Publicado: (2020)

Probiotics' effects on the incidence of nosocomial pneumonia in critically ill patients: a systematic review and meta-analysis
por: Liu, Kai-xiong, et al.
Publicado: (2012)

Systematic review: The relation between nutrition and nosocomial pneumonia: randomized trials in critically ill patients
por: Cook, Deborah, et al.
Publicado: (1997)

Correlation between the drug concentration of polymyxin B and polymyxin B‐associated acute kidney injury in critically ill patients: A prospective study
por: Xu, Ying, et al.
Publicado: (2022)

Trough concentration may not be a good target for polymyxin B therapeutic drug monitoring
por: Zhao, Yuhua, et al.
Publicado: (2023)

Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
por: Liu, Li, et al.
Publicado: (2020)

Parenteral polymyxins: Assessing efficacy and safety in critically ill patients with renal dysfunction
por: Sekhri, Kavita, et al.
Publicado: (2013)

Comparison of clinical outcomes in critically ill COVID-19 patients on mechanical ventilation with nosocomial pneumonia between Alpha and Omicron variants
por: Sun, Chuan-Yen, et al.
Publicado: (2023)

Recurrence of Gram-negative nosocomial pneumonia in the critically ill patient following short-course antibiotic therapy
por: Pugh, Richard, et al.
Publicado: (2007)

Oral chlorhexidine to prevent nosocomial pneumonia in critically ill patients: a systematic review and meta-analysis
por: Pugh, RJ, et al.
Publicado: (2010)

Use of polymyxin B with different administration methods in the critically ill patients with ventilation associated pneumonia: a single-center experience
por: Shi, Rupeng, et al.
Publicado: (2023)

Impact of the use of nephrotoxic drugs in critically ill pediatric patients
por: Almeida, Jáder Pereira, et al.
Publicado: (2020)

Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study
por: Aggarwal, Ritesh, et al.
Publicado: (2018)

Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study
por: Chen, Chih-Yu, et al.
Publicado: (2022)

Population Pharmacokinetics of Caspofungin among Extracorporeal Membrane Oxygenation Patients during the Postoperative Period of Lung Transplantation
por: Wang, Qianlin, et al.
Publicado: (2020)

Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae: A Propensity Score-Matched Cohort Study
por: Zha, Lei, et al.
Publicado: (2023)

Efficacy and safety of polymyxin E sulfate in the treatment of critically ill patients with carbapenem-resistant organism infections
por: Lu, Xin, et al.
Publicado: (2022)

Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Evaluation of nosocomial infections and risk factors in critically ill patients
por: Ozer, Burcin, et al.
Publicado: (2011)

Nosocomial Outbreak of Extensively Drug-Resistant (Polymyxin B and Carbapenem) Klebsiella pneumoniae in a Collapsed University Hospital Due to COVID-19 Pandemic
por: Gaspar, Gilberto G., et al.
Publicado: (2022)

Assessing the Risk of Nephrotoxicity Associated With Non-renally Adjusted Intravenous Polymyxin B Compared with Traditional Dosing
por: Maniara, Bejoy, et al.
Publicado: (2017)

Risks of Polymyxin B Nephrotoxicity and Its Precursors in the Intensive Care Unit: A Retrospective Cohort Study
por: Özkarakaş, Hüseyin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nduntdhcajeibb2gkajd1fonrb